Genor Biopharma Holdings Limited (HK:6998)
:6998
Want to see HK:6998 full AI Analyst Report?
Top Page
Genor Biopharma Holdings Limited
(6998)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$2.00
▼(-34.64% Downside)
Action:Reiterated
Date:05/21/26
The score is driven primarily by improved 2025 fundamentals (profitability and positive free cash flow) but tempered by historical volatility and the sharp increase in debt. Technically, the stock is in a clear downtrend (below major moving averages with negative MACD), despite oversold readings. Valuation is a supportive factor given the very low P/E.
Positive Factors
2025 Profitability Turnaround
The sharp 2025 swing to significant revenue and positive margins demonstrates the company can scale biologics commercialization and convert R&D into profitable sales. Durable profitability supports reinvestment into pipelines, funds commercialization and reduces reliance on external capital over multiple years.
Negative Factors
Historical revenue and profit volatility
Multi-year instability in revenue and recurring losses through 2020–2024 weakens confidence that 2025’s improvement is durable. This history raises execution risk for commercialization and makes forecasting margins and cash flows across 2–6 months to years less reliable.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Profitability Turnaround
The sharp 2025 swing to significant revenue and positive margins demonstrates the company can scale biologics commercialization and convert R&D into profitable sales. Durable profitability supports reinvestment into pipelines, funds commercialization and reduces reliance on external capital over multiple years.
Read all positive factors
Genor Biopharma Holdings Limited (6998) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.51B
Dividend YieldN/A
Average Volume (3M)909.38K
Price to Earnings (P/E)5.1
Beta (1Y)0.45
Revenue Growth1117.02%
EPS GrowthN/A
CountryHK
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,011,213,700
10 Day Avg. Volume879,300
30 Day Avg. Volume909,383
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.17
Price to Sales (P/S)1.86
P/FCF Ratio11.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genor Biopharma Holdings Limited Business Overview & Revenue Model
Company Description
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) bi...
How the Company Makes Money
null...
Genor Biopharma Holdings Limited Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
63
Positive
Cash Flow
56
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.42B | 206.23M | 0.00 | 15.93M | 0.00 |
| Gross Profit | 1.34B | 204.89M | 0.00 | 14.95M | 0.00 |
| EBITDA | 929.10M | -5.15M | -551.01M | -675.89M | -840.19M |
| Net Income | 388.93M | -51.28M | -674.36M | -730.40M | -865.37M |
Balance Sheet | |||||
| Total Assets | 6.61B | 1.29B | 1.45B | 2.12B | 2.86B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.06B | 1.17B | 1.59B | 2.20B |
| Total Debt | 1.49B | 911.00K | 7.16M | 28.59M | 57.41M |
| Total Liabilities | 2.75B | 138.05M | 256.18M | 309.87M | 369.73M |
| Stockholders Equity | 3.86B | 1.15B | 1.19B | 1.80B | 2.49B |
Cash Flow | |||||
| Free Cash Flow | 404.05M | -123.55M | -426.15M | -590.56M | -695.13M |
| Operating Cash Flow | 451.73M | -121.98M | -425.12M | -577.61M | -623.74M |
| Investing Cash Flow | 1.24B | 8.01M | 5.99M | -12.94M | -54.26M |
| Financing Cash Flow | -744.78M | -1.56M | -6.82M | -57.39M | 17.57M |
Genor Biopharma Holdings Limited Technical Analysis
Negative
3.06
Price Trends
2.68
Negative
2.68
Negative
3.21
Negative
Market Momentum
-0.29
Positive
18.68
Positive
5.34
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6998, the sentiment is Negative. The current price of 3.06 is above the 20-day moving average (MA) of 2.21, above the 50-day MA of 2.68, and below the 200-day MA of 3.21, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 18.68 is Positive, neither overbought nor oversold. The STOCH value of 5.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6998.
Genor Biopharma Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.51B | 5.10 | 2.04% | ― | 1117.02% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.40B | -5.82 | -12.64% | ― | -53.85% | 12.23% | |
45 Neutral | HK$2.81B | -22.70 | -14.78% | ― | -32.12% | -393.23% | |
44 Neutral | HK$684.00M | -8.24 | -15.19% | ― | ― | 20.16% | |
42 Neutral | HK$800.12M | -1.25 | -75.15% | ― | 79.76% | 7.68% | |
41 Neutral | HK$438.43M | -1.61 | 293.08% | ― | ― | -25.79% |
* Healthcare Sector Average
HK:6998
Genor Biopharma Holdings Limited
1.75
-0.97
-35.66%
HK:1875
TOT BIOPHARM International Co. Ltd.
3.64
1.71
88.60%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
1.92
-0.08
-4.00%
HK:2185
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
2.81
-0.50
-15.11%
HK:6622
Zhaoke Ophthalmology Ltd.
2.55
-0.62
-19.56%
HK:6978
Immunotech Biopharm Ltd
0.71
-2.35
-76.80%
Genor Biopharma Holdings Limited Corporate Events
Edding Genor Reshapes Company Secretariat as Hong Kong Grants Governance Waiver
May 13, 2026
Edding Genor Group Holdings announced that joint company secretary Zhai Jing will resign effective 13 May 2026 to focus on business development, with the board noting she has no disagreements and no issues requiring shareholder attention. The move...
Edding Genor’s GB261 Gains Momentum as UCB Moves to Acquire Licensee Candid Therapeutics
May 4, 2026
Edding Genor has been advancing GB261 through a global licensing strategy, having granted Candid Therapeutics exclusive rights outside Greater China to develop and commercialize the bispecific antibody. The deal structure combines equity participa...
Edding Genor Calls 2026 AGM, Seeks Fresh Share Repurchase and Issuance Mandates
Apr 15, 2026
Edding Genor Group Holdings has convened its annual general meeting for 26 June 2026 in Shanghai, where shareholders will review and adopt the audited financial statements for the year ended 31 December 2025. The meeting will also consider the re-...
Edding Genor Boosts Profit as Landmark Biotech Merger Drives New Growth
Mar 27, 2026
Edding Genor Group reported revenue of RMB2,487.5 million for 2025, with net profit rising to RMB399.3 million and cash and cash equivalents climbing to RMB1,054.9 million by year-end, indicating strengthened financial resilience. Adjusted net pro...
Edding Genor Details Board and Committee Structure
Mar 27, 2026
Edding Genor Group Holdings Limited announced the current composition of its board of directors, listing two executive directors, two non-executive directors, and three independent non-executive directors. The company also detailed the membership ...
Edding Genor Sets March 2026 Board Meeting to Approve 2025 Results
Mar 17, 2026
Edding Genor Group Holdings has scheduled a board meeting for 27 March 2026 to review and approve the annual results for the year ended 31 December 2025 and to authorize their publication. The board will also consider whether to recommend a final ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.